homocysteine measurement
Diagnostic Testmeasuring the serum level of homocysteine
NCT Number: NCT06413576
Preeclampsia is a disorder characterized by the new onset of hypertension and proteinuria typically presenting after 20 weeks of gestation. Elevated circulating homocysteine is a risk factor for endothelial dysfunction and vascular diseases such as atherosclerosis and occlusive disorders. Our study is to investigate the association between elevated blood homocysteine levels and complications in pregnant women in order to conclude the clinical utility of homocysteine as a marker of severity in the cases of pre-eclampsia.
Looking for future studies?
Notify MeFemale
Observational
Ain shams University, Cairo, Cairo Governorate, Egypt
Hypertensive disorders of pregnancy are an important cause of morbidity and mortality among mothers and infants. Preeclampsia is a pregnancy-related hypertensive disorder occurring usually after 20 weeks of gestation. It is associated with fetal growth restriction, low birth weight, preterm birth, respiratory distress syndrome, and admission to a neonatal intensive care unit. According to a systemic review and meta-analysis published in 2013, preeclampsia has a noticeable relationship with an increased risk of developing hypertension, ischemic heart disease, and cerebrovascular accident in later life.
There is already abundant evidence indicating that elevated serum homocysteine levels may be related to the risk of coronary, cerebral, and peripheral arterial diseases. Elevated circulating homocysteine is a risk factor of endothelial dysfunction and vascular diseases such as atherosclerosis and occlusive disorders. Normally, homocysteine levels decline throughout pregnancy and since the vascular alterations brought on by homocysteine are comparable to those brought on by hypertensive disorders of pregnancy, it can be assumed that high levels of homocysteine are linked to the hypertensive disorder spectrum. Homocysteine has been shown to produce oxidative stress and endothelial dysfunction, endothelial cell injury and thrombus formation and thereby producing pre-eclampsia.
Estimation of homocysteine may help to predict and prevent pre-eclampsia and eclampsia, thus reducing the undesired outcome of pregnancy.
Among various studies, there is a lack of consistency in the reported results that support the link between maternal homocysteine concentrations assessed throughout each of the three trimesters of pregnancy and difficulties caused by the placenta.
our study investigate the relation between the level of homocysteine and severity of preeclampsia.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
measuring the serum level of homocysteine
Time frame: within 24 hours postoperative(post delivery)
Quantitative measurement of the serum level of homocysteine. The measurement will be done using a commercially available sandwich enzyme linked immunosorbent assay (ELIZA) kit supplied by ( Bioassay technology laboratory) according to the manufacturer's instructions.nthe results will be expressed in ng/ml. Absorbance of standards and samples were measured at 450 nm using a microtiter plate ELISA reader .
Time frame: within 24 hours postoperative
the co relation between levels of homocysteine and degree of severity of preeclampsia using spearman rank correlation co efficient
Ain Shams University
Other
The Clinical Utility of Homocysteine in Critically Ill Preeclampsia Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06651879
Critical Illness, Difficult; Intubation, Postpartum, During Puerperium
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT06122220
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Panama City, Provincia de Panamá, Panama
View Trial DetailsNCT06640842
Alzheimer Disease, Brain Diseases
Kansas City, Kansas, United States
View Trial DetailsNCT06069102
Cardiovascular Diseases, Eclampsia
Pittsburgh, Pennsylvania, United States
View Trial Details